Johnson & Johnson $JNJ Shares Acquired by Wealthfront Advisers LLC

Wealthfront Advisers LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 13.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 286,462 shares of the company’s stock after purchasing an additional 34,394 shares during the period. Wealthfront Advisers LLC’s holdings in Johnson & Johnson were worth $43,757,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Oppenheimer Asset Management Inc. increased its position in Johnson & Johnson by 0.4% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 659,253 shares of the company’s stock valued at $100,701,000 after acquiring an additional 2,488 shares during the period. QV Investors Inc. increased its position in Johnson & Johnson by 0.6% in the 2nd quarter. QV Investors Inc. now owns 101,240 shares of the company’s stock valued at $15,464,000 after acquiring an additional 580 shares during the period. University of Texas Texas AM Investment Management Co. increased its position in Johnson & Johnson by 844.3% in the 2nd quarter. University of Texas Texas AM Investment Management Co. now owns 52,389 shares of the company’s stock valued at $8,002,000 after acquiring an additional 46,841 shares during the period. Fiduciary Wealth Partners LLC increased its position in Johnson & Johnson by 71.1% in the 2nd quarter. Fiduciary Wealth Partners LLC now owns 3,126 shares of the company’s stock valued at $478,000 after acquiring an additional 1,299 shares during the period. Finally, Whipplewood Advisors LLC increased its position in Johnson & Johnson by 9.8% in the 2nd quarter. Whipplewood Advisors LLC now owns 1,797 shares of the company’s stock valued at $274,000 after acquiring an additional 161 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $190.38 on Monday. The business’s 50 day simple moving average is $182.26 and its 200-day simple moving average is $166.37. The firm has a market capitalization of $458.69 billion, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. HSBC lifted their price objective on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Loop Capital set a $190.00 price objective on Johnson & Johnson in a report on Wednesday. Finally, Weiss Ratings raised Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.